Trial Profile
Optical Coherence TomOgraphy Assessment of the Excel Drug-Eluting Stent With BiodegradablE polymeR vs. the Cypher Drug-Eluting Stent With Permanent Polymer.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Nov 2009
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms OCTOBER
- 18 Nov 2009 New trial record